<DOC>
	<DOCNO>NCT00160966</DOCNO>
	<brief_summary>The aim study characterize evaluate risk factor polyomavirus nephropathy ( PVN ) include impact three immunosuppressive regimen .</brief_summary>
	<brief_title>Impact Immunosuppressive Regimens Polyomavirus-related Transplant Nephropathy</brief_title>
	<detailed_description>Polyomavirus nephropathy ( PVN ) emerge cause renal transplant loss . Until risk factor PVN poorly understood . Tacrolimus ( Tacr ) mycophenolate mofetil ( MMF ) think associate high risk develop PVN . However , way Tacr MMF might enhance susceptibility PVN remain largely unknown . In prospective study analyze whether difference immune-reactivity pattern ( Th1 , Th2 , B cell monocyte response , sCD30 , immunoregulatory antibody ) renal transplant patient induced different immunosuppressive regimen ( cyclosporine A [ CsA ] /MMF , Tacr/MMF , Tacr/MMF conversion Tacr/Everolimus [ ERL ] ) cytokine promoter gene polymorphism may account different risk develop PVN . Comparison ( ) : renal transplant recipient stratify accord relative immunological risk ( group 1 : low risk ( primary recipient without pre-immunization [ PRA &lt; 5 % ] ) ; group 2 : moderate risk ( group 2a : primary recipient low pre-immunization [ PRA 6-20 % ] ; group 2b : re-transplanted patient ) ; group 3 : high risk ( re-transplanted patient history vascular rejection recipient first graft high pre-immunization [ PRA &gt; 20 % ] ) randomize treated one three immunosuppressive regimen ( CsA/MMF , Tacr/MMF , Tacr/MMF subsequent conversion Tacr/ERL ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polyomavirus Infections</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Cadaver kidney live donor kidney transplant recipient Primary , secondary , tertiary transplant recipient Preimmunized preimmunized transplant recipient Age &gt; 18 year Contraindications administration one four study drug History severe gastrointestinal morbidity Age &lt; 18 year Pregnant breast feed woman Rejection effective contraceptive method young woman Combined kidney islet cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>kidney transplantation</keyword>
	<keyword>polyoma virus associate transplant nephropathy</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>everolimus</keyword>
	<keyword>cyclosporin A</keyword>
	<keyword>BK virus PCR</keyword>
	<keyword>viruria screen</keyword>
	<keyword>BK polyomavirus</keyword>
	<keyword>immunosuppression</keyword>
</DOC>